Pain:羟考酮与纳洛酮是否利于硬膜外镇痛?

2017-12-16 MedSci MedSci原创

胸腔硬膜外镇痛(TEA)可以增强肠道手术后的患者恢复。术后早期予以羟考酮或羟考酮/纳洛酮缓释口服制剂可以作为减少TEA持续时间的镇痛第二步,并具有一定的潜在作用。近期,一项发表在杂志Pain上的研究进行了一个假设:羟考酮会减少TEA的持续时间,并与纳洛酮联合保持胃肠功能。此项研究在2015年9月至2017年2月期间进行,共有90名接受开放式膀胱切除术和尿流改道术的患者参加了这项随机双盲三臂平行组安

胸腔硬膜外镇痛(TEA)可以增强肠道手术后的患者恢复。术后早期予以羟考酮或羟考酮/纳洛酮缓释口服制剂可以作为减少TEA持续时间的镇痛第二步,并具有一定的潜在作用。

近期,一项发表在杂志Pain上的研究进行了一个假设:羟考酮会减少TEA的持续时间,并与纳洛酮联合保持胃肠功能。

此项研究在2015年9月至2017年2月期间进行,共有90名接受开放式膀胱切除术和尿流改道术的患者参加了这项随机双盲三臂平行组安慰剂对照的单中心试验。排除标准是已知的对羟考酮/纳洛酮过敏,肺疾病和肝病的患者。自术后第3天,患者每12小时接受一次羟考酮,羟考酮/纳洛酮或安慰剂(每组30例)。研究者们试图减少硬膜外药物的输注速率,目的是维持静止时的疼痛强度<3,并且在6小时内动员时的疼痛强度<5(数字评分)。主要终点是TEA持续时间和次要终点是胃肠功能恢复。

研究结果显示:羟考酮/纳洛酮(6.7 [范围3.1-10.3]天),羟考酮(7.0 [3.0-9.1])或安慰剂(6.4 [3.1-8.4])治疗组患者的TEA中位持续时间没有差异;P = 0.88。与安慰剂组相比,羟考酮组的首次排便时间延长(差异22.48小时±8.95; P = 0.037)。在羟考酮组中,研究者们发现8/30例肠梗阻患者(27%),羟考酮/纳洛酮组为2/28(7%),而安慰剂组为2/30(7%); (P = 0.031)。

此项研究结果表明:有或没有纳洛酮的羟考酮并不能减少TEA的持续时间。单独使用羟考酮导致肠功能的恢复延迟,而联合使用与安慰剂没有区别。

原始出处:
Schneider MP, Löffel LM, et al. Can early oral prolonged-release oxycodone with or without naloxone reduce the duration of epidural analgesia after cystectomy? A 3-arm, randomized, double-blind, placebo-controlled trial. Pain. 2017 Nov 20. doi: 10.1097/j.pain.0000000000001112. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1948438, encodeId=296b194843847, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Mon Jun 18 18:24:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937137, encodeId=77bf193e13797, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Apr 13 00:24:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298074, encodeId=088b2980e4f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/23/7e052413cca748d8a3ad7be705b0b6f4.jpg, createdBy=4d292156689, createdName=笑香儿, createdTime=Tue Mar 20 13:39:22 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924106, encodeId=39411924106b0, content=<a href='/topic/show?id=30afe735060' target=_blank style='color:#2F92EE;'>#纳洛酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77350, encryptionId=30afe735060, topicName=纳洛酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Tue Mar 20 22:24:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355261, encodeId=3fe113552610d, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 18 03:24:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1948438, encodeId=296b194843847, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Mon Jun 18 18:24:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937137, encodeId=77bf193e13797, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Apr 13 00:24:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298074, encodeId=088b2980e4f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/23/7e052413cca748d8a3ad7be705b0b6f4.jpg, createdBy=4d292156689, createdName=笑香儿, createdTime=Tue Mar 20 13:39:22 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924106, encodeId=39411924106b0, content=<a href='/topic/show?id=30afe735060' target=_blank style='color:#2F92EE;'>#纳洛酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77350, encryptionId=30afe735060, topicName=纳洛酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Tue Mar 20 22:24:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355261, encodeId=3fe113552610d, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 18 03:24:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1948438, encodeId=296b194843847, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Mon Jun 18 18:24:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937137, encodeId=77bf193e13797, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Apr 13 00:24:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298074, encodeId=088b2980e4f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/23/7e052413cca748d8a3ad7be705b0b6f4.jpg, createdBy=4d292156689, createdName=笑香儿, createdTime=Tue Mar 20 13:39:22 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924106, encodeId=39411924106b0, content=<a href='/topic/show?id=30afe735060' target=_blank style='color:#2F92EE;'>#纳洛酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77350, encryptionId=30afe735060, topicName=纳洛酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Tue Mar 20 22:24:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355261, encodeId=3fe113552610d, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 18 03:24:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
    2018-03-20 笑香儿

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1948438, encodeId=296b194843847, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Mon Jun 18 18:24:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937137, encodeId=77bf193e13797, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Apr 13 00:24:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298074, encodeId=088b2980e4f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/23/7e052413cca748d8a3ad7be705b0b6f4.jpg, createdBy=4d292156689, createdName=笑香儿, createdTime=Tue Mar 20 13:39:22 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924106, encodeId=39411924106b0, content=<a href='/topic/show?id=30afe735060' target=_blank style='color:#2F92EE;'>#纳洛酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77350, encryptionId=30afe735060, topicName=纳洛酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Tue Mar 20 22:24:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355261, encodeId=3fe113552610d, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 18 03:24:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1948438, encodeId=296b194843847, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Mon Jun 18 18:24:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937137, encodeId=77bf193e13797, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Apr 13 00:24:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298074, encodeId=088b2980e4f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/23/7e052413cca748d8a3ad7be705b0b6f4.jpg, createdBy=4d292156689, createdName=笑香儿, createdTime=Tue Mar 20 13:39:22 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924106, encodeId=39411924106b0, content=<a href='/topic/show?id=30afe735060' target=_blank style='color:#2F92EE;'>#纳洛酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77350, encryptionId=30afe735060, topicName=纳洛酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Tue Mar 20 22:24:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355261, encodeId=3fe113552610d, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 18 03:24:00 CST 2017, time=2017-12-18, status=1, ipAttribution=)]
    2017-12-18 zhaojie88

相关资讯

Med Sci Monit:羟考酮预处理能同时减少快速顺序麻醉诱导中依托咪酯诱发的肌阵挛和罗库溴铵诱发的回避反应

依托咪酯和罗库溴铵通常被同时用于快速顺序诱导麻醉。然而,羟考酮预处理对肌阵挛和回避反应的影响并没有文献报道。本研究的目的是评估羟考酮预处理对快速顺序诱导麻醉中依托咪酯诱发的肌阵挛和罗库溴铵诱发的回避反应的发生率和严重程度的影响。

FDA更新羟考酮新剂型的说明书

    2013年4月16日,美国食品与药物管理局(FDA)批准了奥施康定(通用名:盐酸羟考酮控释片)新剂型说明书的更新。更改后的说明书显示,因该药可能会导致滥用,为减少滥用可通过嗅吸法途径给药。   另外,与奥施康定的新剂型相比,原来的盐酸羟考酮控释片有同样的治疗获益,但其获益未超出药物滥用风险,因此FDA决定撤出其销售权,同时FDA将不接受或批准任何原来的盐酸羟考酮控释片的非专利